Trials / Unknown
UnknownNCT05227950
Cell-free DNA Quantification for Predictive Marker of Palliative Chemotherapy
Usefulness of Cell-free DNA Quantification With Fluorescent Assay in Response Evaluation of Palliative Chemotherapy
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Pusan National University Yangsan Hospital · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study is design to address, as follows: 1. correlation between fluorescence-based CFD measurements and tumor burden (primary tumor size, number of metastatic sites) 2. fluorescence-based CFD measurements and changes are related to tumor response. Based on the results of this study, the role of fluorescence-based CFD as a predictive biomarker for palliative chemotherapy is to be confirmed.
Detailed description
* It is important to check the response to chemotherapy. Currently, it is mostly evaluated as a radiologic response or, rarely the change of tumor markers. * In the case of radiologic response tests at intervals of 6-8 weeks, there are cases where the economic burden and radiation exposure risk, additionally evaluation lesion is lack in a few case. Except for prostate cancer and ovarian cancer, the majority of carcinomas do not have cancer markers for assessing treatment response. Therefore, there is a need for biomarkers that can predict the response of anticancer treatment. * In many studies, it has been reported that various types of circulating cell free DNA (CFD) are increased in various cancer types. * Recently, a fluorescence based CFD method that can directly measure nucleic acids without a DNA extraction process has been developed, which makes testing simpler and more economical, and can be conveniently applied to cancer diagnosis and treatment response. * This study is plan to evaluate the relationship between fluorescence-based CFD and treatment response in patients starting palliative chemotherapy, and check whether it can serve as a response evaluation for palliative chemotherapy.
Conditions
Timeline
- Start date
- 2022-01-01
- Primary completion
- 2024-06-30
- Completion
- 2024-06-30
- First posted
- 2022-02-08
- Last updated
- 2022-02-08
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05227950. Inclusion in this directory is not an endorsement.